New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.
Related Questions
How will the new evidence affect Castle Biosciences' revenue forecasts and valuation?
What is the expected timeline for broader adoption and reimbursement coverage of the DecisionDx‑SCC test?
How does this development compare to competitors' offerings in the high‑risk cutaneous squamous cell carcinoma diagnostics market?